AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback